skip to content

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.